Wasawas, Nilda T.
HRN: 13-38-22 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/25/2023
LEVOFLOXACIN 500MG (TAB)
03/25/2023
04/01/2023
PO
750mg
OD
Infected Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes